BIIB · NASDAQ
Biogen (BIIB) Stock Price & Fundamentals
Biogen (BIIB) closed at $699.87 on Oct 9, 2026, down 0.60% from the previous close of $704.11.
Share price, past year
1Y +29.78%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $699.87 |
| Sep 30, 2026 | $712.07 |
| Aug 31, 2026 | $693.43 |
| Jul 31, 2026 | $689.92 |
| Jun 30, 2026 | $684.75 |
| May 29, 2026 | $660.75 |
| Apr 30, 2026 | $655.03 |
| Mar 31, 2026 | $660.96 |
| Feb 27, 2026 | $624.27 |
| Jan 30, 2026 | $625.81 |
| Dec 31, 2025 | $607.30 |
| Nov 28, 2025 | $569.98 |
| Oct 31, 2025 | $550.60 |
Key statistics
- Market cap
- $102.74B
- P/E (TTM)
- 75.3
- EPS (TTM)
- $9.30
- Revenue (TTM)
- $9.94B
- Net income (TTM)
- $1.37B
- Shares outstanding
- 146.8M
- Dividend yield
- —
- 52-week range
- $539.26 – $729.81
Biogen's market cap is $102.74B, based on a share price of $699.87 and 146.8M shares outstanding as of Dec 31, 2025.
Financials
Biogen reported revenue of $9.89B for fiscal 2025, up 2.22% from fiscal 2024.
Biogen earned net income of $1.29B in fiscal 2025, a net margin of 13.1%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $9.89B | +2.2% | $1.29B | 13.1% | $8.79 | $2.05B |
| FY2024ended Dec 31, 2024 | $9.68B | −1.6% | $1.63B | 16.9% | $11.18 | $2.72B |
| FY2023ended Dec 31, 2023 | $9.84B | −3.3% | $1.16B | 11.8% | $7.97 | $1.27B |
| FY2022ended Dec 31, 2022 | $10.17B | −7.4% | $3.05B | 30.0% | $20.87 | $1.14B |
| FY2021ended Dec 31, 2021 | $10.98B | −18.3% | $1.56B | 14.2% | $10.40 | $3.38B |
| FY2020ended Dec 31, 2020 | $13.44B | −6.5% | $4.00B | 29.8% | $24.80 | $3.81B |
| FY2019ended Dec 31, 2019 | $14.38B | +6.9% | $5.89B | 41.0% | $31.42 | $6.56B |
| FY2018ended Dec 31, 2018 | $13.45B | +9.6% | $4.43B | 32.9% | $21.58 | $5.42B |
| FY2017ended Dec 31, 2017 | $12.27B | +7.2% | $2.54B | 20.7% | $11.92 | $3.68B |
| FY2016ended Dec 31, 2016 | $11.45B | — | $3.70B | 32.3% | $16.93 | $3.97B |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $2.48B | $319.50M | $2.15 |
| Q4 FY2025ended Dec 31, 2025 | $2.28B | −$48.90M | −$0.35 |
| Q3 FY2025ended Sep 30, 2025 | $2.53B | $466.50M | $3.17 |
| Q2 FY2025ended Jun 30, 2025 | $2.65B | $634.80M | $4.33 |
| Q1 FY2025ended Mar 31, 2025 | $2.43B | $240.50M | $1.64 |
| Q4 FY2024ended Dec 31, 2024 | $2.45B | $266.70M | $1.82 |
| Q3 FY2024ended Sep 30, 2024 | $2.47B | $388.50M | $2.66 |
| Q2 FY2024ended Jun 30, 2024 | $2.46B | $583.60M | $4.00 |
Company profile
- Name
- Biogen Inc.
- Ticker
- BIIB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 225 Binney Street, Cambridge, MA 02142
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000875045
Recent SEC filings
- Jul 29, 2026
- Jul 29, 2026
- Jul 1, 2026
- Jun 10, 2026
- May 14, 2026
- Apr 29, 2026
- Apr 29, 2026
- Apr 6, 2026
Frequently asked questions
What is Biogen's stock price?
Biogen (BIIB) closed at $699.87 on Oct 9, 2026, down 0.60% from the previous close of $704.11.
What is Biogen's market cap?
Biogen's market cap is $102.74B, based on a share price of $699.87 and 146.8M shares outstanding as of Dec 31, 2025.
How much revenue does Biogen make?
Biogen reported revenue of $9.89B for fiscal 2025, up 2.22% from fiscal 2024.
What is BIIB's P/E ratio?
Biogen's price-to-earnings ratio is 75.3, based on trailing twelve-month diluted EPS of $9.30.
Does Biogen pay a dividend?
Biogen's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Biogen Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures